SAN DIEGO -- AXS-12 (reboxetine), an investigational treatment for narcolepsy, reduced weekly cataplexy attacks and in some cases provided complete remission, the phase III SYMPHONY study showed. From ...
When entrepreneur and author Michelle Weger first started falling asleep in her university classrooms at 17, the teenager who ...
Matthew Horsnell began falling asleep for no reason when he was in sixth grade. “I would go to bed at 8:30 at night, yet every morning I would wake up and struggle to get out of bed,” said Horsnell, ...
AXS-12 reduced the frequency of cataplexy attacks per week compared with placebo (P =.017). Topline results were announced from a phase 3 trial evaluating AXS-12 (reboxetine) in patients with ...
Narcolepsy, with or without cataplexy, can have a substantial detrimental effect on well-being and quality of life. Because there is no cure for this condition, current treatments aim to improve ...
SAN DIEGO — The investigational drug AXS-12 (reboxetine, Axsome Therapeutics) is safe and effective for the treatment of cataplexy (emotionally induced muscle weakness) and excessive daytime ...
People with narcolepsy often need to take medicines to manage their symptoms. Many of these medicines carry a high risk for abuse or misuse, so there are restrictions on how they are prescribed and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback